145 related articles for article (PubMed ID: 7840515)
1. Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor.
Frković-Grazio S; Kraljić I; Trnski D; Tarle M
Anticancer Res; 1994; 14(5B):2151-6. PubMed ID: 7840515
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
3. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
4. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A
Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
6. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
7. Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma.
Huan Y; Idrees M; Gribetz ME; Unger PD
Ann Diagn Pathol; 2008 Apr; 12(2):142-5. PubMed ID: 18325477
[TBL] [Abstract][Full Text] [Related]
8. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
9. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
Parwani AV; Marlow C; Demarzo AM; Mikolajczyk SD; Rittenhouse HG; Veltri RW; Chan TY
Am J Surg Pathol; 2006 Oct; 30(10):1231-6. PubMed ID: 17001152
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
12. Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases.
Mai KT; Roustan Delatour NL; Assiri A; Al-Maghrabi H
Diagn Cytopathol; 2007 Feb; 35(2):91-5. PubMed ID: 17230567
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
14. [Neuroendocrine differentiation and markers of cell proliferation in a group of patients with prostate adenocarcinoma and normal or high serum prostate-specific antigen levels].
Feria-Bernal G; García-Gonzalez VM; Figueroa-Granados V; Martinez-Benítez B; Uribe-Uribe NO
Gac Med Mex; 2006; 142(6):441-6. PubMed ID: 17201105
[TBL] [Abstract][Full Text] [Related]
15. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
16. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract][Full Text] [Related]
17. Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases.
Parwani AV; Herawi M; Epstein JI
Am J Surg Pathol; 2006 Oct; 30(10):1254-9. PubMed ID: 17001156
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical study of neuroendocrine cells and prostate-specific antigen in prostate carcinoma].
Yao GY; Lai MD; Chen PH
Zhonghua Yi Xue Za Zhi; 1994 Mar; 74(3):161-2, 191-2. PubMed ID: 7522941
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
Mhawech P; Uchida T; Pelte MF
Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
[TBL] [Abstract][Full Text] [Related]
20. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
